To ensure enough raw materials for glycolysis, glioma cells and GSCs took up glucose efficiently via elevated glucose transporter (GLUT) (Libby et al., 2018), of which the level of GLUT3 is characteristic (Xu et al., 2015; Zheng et al., 2016), relating to the resistance to antiangiogenic drugs (Kuang et al., 2017). This evidence concerns the gene SLC2A1 and central nervous system cancer.